X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1068) 1068
Publication (61) 61
Book Chapter (20) 20
Conference Proceeding (4) 4
Book Review (3) 3
Paper (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
thienopyridines (537) 537
humans (449) 449
index medicus (381) 381
thienopyridine (365) 365
clopidogrel (350) 350
male (240) 240
aspirin (217) 217
prasugrel (207) 207
ticlopidine - analogs & derivatives (203) 203
animals (167) 167
female (167) 167
platelet aggregation inhibitors - therapeutic use (166) 166
pharmacology & pharmacy (158) 158
percutaneous coronary intervention (152) 152
cardiac & cardiovascular systems (148) 148
platelet aggregation inhibitors - pharmacology (130) 130
middle aged (128) 128
antiplatelet therapy (122) 122
prasugrel hydrochloride (116) 116
acute coronary syndromes (115) 115
platelet aggregation inhibitors - adverse effects (115) 115
chemistry, organic (112) 112
aged (108) 108
ticlopidine - therapeutic use (96) 96
thrombosis (94) 94
platelet aggregation inhibitors - administration & dosage (93) 93
peripheral vascular disease (92) 92
acute coronary syndrome (86) 86
hematology (85) 85
myocardial-infarction (83) 83
ticagrelor (83) 83
platelet aggregation - drug effects (81) 81
risk factors (75) 75
platelets (74) 74
aspirin - therapeutic use (73) 73
rats (71) 71
treatment outcome (71) 71
adult (70) 70
thiophenes - pharmacology (70) 70
ticlopidine (68) 68
ticlopidine - adverse effects (66) 66
ticlopidine - pharmacology (66) 66
derivatives (65) 65
ticlopidine - administration & dosage (64) 64
blood platelets - drug effects (61) 61
drug therapy, combination (61) 61
active metabolite (59) 59
p2y (59) 59
piperazines - pharmacology (59) 59
azepines - pharmacology (58) 58
chemistry, multidisciplinary (58) 58
aggregation (55) 55
platelet aggregation (53) 53
platelet aggregation inhibitors - pharmacokinetics (53) 53
blood platelets (52) 52
pyridine (52) 52
therapy (51) 51
drug therapy (50) 50
chemistry, medicinal (49) 49
inhibitors (49) 49
acute coronary syndrome - drug therapy (48) 48
chemistry (48) 48
pharmacokinetics (48) 48
pyridines - pharmacology (48) 48
antiplatelet (47) 47
dose-response relationship, drug (47) 47
stents (47) 47
time factors (47) 47
chemistry, inorganic & nuclear (46) 46
coronary heart disease (46) 46
platelet activating factor - antagonists & inhibitors (46) 46
aspirin - administration & dosage (45) 45
piperazines - pharmacokinetics (45) 45
analysis (44) 44
drug interactions (44) 44
thienopyridines - therapeutic use (44) 44
thiophenes - therapeutic use (44) 44
adp (43) 43
molecular structure (43) 43
piperazines - therapeutic use (43) 43
thiophenes - pharmacokinetics (43) 43
triazoles - pharmacology (43) 43
abridged index medicus (42) 42
cardiovascular (42) 42
inhibition (42) 42
purinergic p2 receptor antagonists (42) 42
stent thrombosis (42) 42
thienopyridines - pharmacology (42) 42
care and treatment (41) 41
trial (40) 40
proton pump inhibitors (39) 39
intervention (38) 38
platelet (38) 38
st-segment elevation (38) 38
acute myocardial-infarction (37) 37
aspirin - adverse effects (37) 37
blood platelets - metabolism (37) 37
cangrelor (37) 37
hemorrhage - chemically induced (37) 37
cardiac patients (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1023) 1023
German (18) 18
French (15) 15
Russian (8) 8
Spanish (7) 7
Japanese (5) 5
Korean (4) 4
Chinese (3) 3
Polish (2) 2
Croatian (1) 1
Danish (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Heart Journal, ISSN 0195-668X, 8/2009, Volume 30, Issue 16, pp. 1964 - 1977
Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. However, the delayed... 
Prasugrel | Clopidogrel | Thienopyridine | Cangrelor | Ticagrelor | Purinoceptor P2Y
Journal Article
Circulation, ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The American Journal of Gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | GASTROENTEROLOGY & HEPATOLOGY | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 11/2014, Volume 22, Issue 21, pp. 5860 - 5870
To identify new potent multidrug resistance modulators, we have synthesized a series of novel thieno[2,3- ]pyridines and furo[2,3- ]pyridines, and examined... 
P-glycoprotein | Thieno[2,3-b]pyridine | Multidrug resistance-associated protein | Multidrug resistance modulators | Breast cancer resistance protein | BCRP | DESIGN | ABC | CHEMISTRY, MEDICINAL | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | THIENOPYRIDINE | CHEMISTRY, ORGANIC | REVERSAL | AGENTS | INHIBITORS | DERIVATIVES | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | NIH 3T3 Cells | Calcium Channels - metabolism | Calcium - metabolism | Drug Resistance, Multiple - drug effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Thienopyridines - metabolism | Neoplasm Proteins - antagonists & inhibitors | Structure-Activity Relationship | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Neoplasm Proteins - metabolism | Thienopyridines - pharmacology | ATP-Binding Cassette Transporters - metabolism | Calcium Channel Blockers - metabolism | Thienopyridines - chemistry | Cell Line | Cell Survival - drug effects | Rats | Multidrug Resistance-Associated Proteins - antagonists & inhibitors | Thienopyridines - toxicity | Muscle, Smooth - metabolism | Calcium Channel Blockers - toxicity | Animals | Calcium Channels - chemistry | Calcium Channel Blockers - chemistry | Protein Binding | Mice | Multidrug Resistance-Associated Proteins - metabolism | ATP-Binding Cassette Transporters - antagonists & inhibitors | Drug resistance in microorganisms | Pyridine
Journal Article
Journal Article
Acta Pharmacologica Sinica, ISSN 1671-4083, 2019
Urea transporters (UTs) are transmembrane proteins selectively permeable to urea and play an important role in urine concentration. UT-knockout mice exhibit... 
urea transporter | drug discovery | electrolytes | diuretics | thienopyridine
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e89S - e119S
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the... 
HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | RESPIRATORY SYSTEM | FIBRINOGEN RECEPTOR ANTAGONISTS | TRANSIENT ISCHEMIC ATTACK | ACUTE MYOCARDIAL-INFARCTION | PLACEBO-CONTROLLED TRIALS | DOUBLE-BLIND | ACUTE CORONARY SYNDROMES | CRITICAL CARE MEDICINE | Dipyridamole - pharmacokinetics | United States | Humans | Thienopyridines - adverse effects | Aspirin - pharmacokinetics | Dose-Response Relationship, Drug | Societies, Medical | Aspirin - adverse effects | Dipyridamole - adverse effects | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Thrombosis - blood | Thrombosis - prevention & control | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Evidence-Based Medicine | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Randomized Controlled Trials as Topic | Thienopyridines - pharmacokinetics | Thienopyridines - therapeutic use | Tetrazoles - therapeutic use | Platelet Activation - drug effects | Thrombosis - drug therapy | Tetrazoles - adverse effects | Tetrazoles - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 01/2019, Volume 127, pp. 151 - 160
Vicagrel, a novel thienopyridine antiplatelet agent, is an analogue of clopidogrel in development for the treatment of acute coronary syndromes. This study... 
Vicagrel | Clopidogrel | Active metabolite | Thienopyridine | Pharmacokinetics | P2Y12 inhibitor
Journal Article
Journal Article
Journal Article
The Journal of Organic Chemistry, ISSN 0022-3263, 08/2018, Volume 83, Issue 15, pp. 8768 - 8774
2-Acylthienopyridines and related heterocycles are readily prepared in moderate to good yields under mild conditions by a nucleophilic thiolation,... 
ANNULATION | THIENOPYRIDINE | CHEMISTRY, ORGANIC | 2-FLUOROPHENYLACETYLENE DERIVATIVES | SULFUR | PRASUGREL | INHIBITORS | IDENTIFICATION | CASCADE SEQUENCE | EXPRESSION | DISCOVERY
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 12/2007, Volume 5, Issue 12, pp. 2429 - 2436
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit the platelet P2Y12 adenosine diphosphate receptor. The... 
clopidogrel | P2Y12 receptor | prasugrel | platelet function | thienopyridines | cytochrome P450 enzymes | Prasugrel | Cytochrome P450 enzymes | receptor | P2Y | Platelet function | Thienopyridines | Clopidogrel | MYOCARDIAL-INFARCTION | STENT THROMBOSIS | ANTIPLATELET THERAPY | ATHEROTHROMBOTIC EVENTS | INCREASED RISK | P2Y receptor | THIENOPYRIDINE P2Y INHIBITOR | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | CORONARY-ARTERY-DISEASE | PLATELET REACTIVITY | ACTIVE METABOLITE | Cytochrome P-450 CYP2C9 | Prasugrel Hydrochloride | Ticlopidine - pharmacology | Area Under Curve | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Mixed Function Oxygenases - metabolism | Reference Values | Thiophenes - blood | Platelet Aggregation Inhibitors - blood | Receptors, Purinergic P2Y12 | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Retrospective Studies | Ticlopidine - pharmacokinetics | Piperazines - pharmacokinetics | Blood Platelets - drug effects | Piperazines - blood | Purinergic P2 Receptor Antagonists | Thiophenes - pharmacology | Genotype | Clinical Trials as Topic | Piperazines - pharmacology | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Polymorphism, Genetic | Cross-Over Studies | Thiophenes - pharmacokinetics | Phenotype | Prodrugs - pharmacokinetics | Blood Platelets - metabolism | Cytochrome P-450 CYP2C19 | Receptors, Purinergic P2 - metabolism | Mixed Function Oxygenases - genetics | Prodrugs - pharmacology | Research Design | Ticlopidine - blood | Adenosine diphosphate | Genetic aspects | Metabolites | Cytochrome P-450
Journal Article